Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major histocompatibility complex, class II, DQ alpha 2 chain (HLA-DQA2) is a protein encoded by the *HLA-DQA2* gene, part of the human leukocyte antigen (HLA) system. This molecule is predominantly expressed on antigen-presenting cells (APCs) and forms part of the MHC class II complex, vital for presentation of exogenous peptide antigens to CD4+ T-cells, thereby modulating adaptive immunity and influencing susceptibility to autoimmune, inflammatory, and infectious diseases. Unlike the closely related HLA-DQA1, HLA-DQA2 exhibits comparatively low expression due to promoter-deficient transcription, and may not efficiently heterodimerize with the usual HLA-DQB chain. Variants at this locus have been linked to protection from narcolepsy, modulation of asthma risk, and lower susceptibility to COVID-19.
For general MHC class II targeting: Blocking or modulating antigen presentation; Altering T-cell activation or tolerance
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major histocompatibility complex, class II, DQ alpha 2 chain (HLA-DQA2).